Hemogenyx Pharmaceuticals Plc
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Vladislav Sandler
- Full Time Employees
- 16
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 60 Gracechurch Street London United Kingdom EC3V 0HR
- IPO Date
- Jan 12, 2021
- Website
- hemogenyx.com
- Similar Companies
- Business
- Hemogenyx Pharmaceuticals Plc (LSE:HEMO; OTC:HOPHF) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies for blood disorders including acute myeloid leukemia, other hematological malignancies, autoimmune diseases and viral infections; its core pipeline encompasses the HG-CT-1 chimeric antigen receptor T-cell (CAR-T) therapy targeting relapsed or refractory acute myeloid leukemia in adults and now cleared for pediatric expansion, the CDX bispecific antibody and CAR-T therapies for patient conditioning in bone marrow transplantation, the Hu-PHEC human phosphorylated heme carrier cell therapy to mitigate transplant toxicities, and the Chimeric Bait Receptor platform programming immune cells against viral pathogens. Founded in 2017 through the acquisition of Hemogenyx Pharmaceuticals Limited by Silver Falcon Plc and headquartered in London with U.S. subsidiaries Hemogenyx Pharmaceuticals LLC and Immugenyx LLC operating from a state-of-the-art research facility in New York City, the company targets patients with life-threatening conditions underserved by existing treatments across North America and Europe. Recent developments include multiple fundraisings in 2025 totaling over £1.5 million through share placings at premiums to market prices including £451,250 in May via allotment to CEO Vladislav Sandler and an institution and £620,000 in August to extend Phase I trials of HG-CT-1, alongside regulatory clearance to initiate pediatric enrollment in the ongoing HG-CT-1 study and continued progress in clinical operations as of late 2025.
Hemogenyx Pharmaceuticals PLC Announces Grant of Options and Extension of Warrant Term
Hemogenyx Pharmaceuticals PLC Announces Final Results
Hemogenyx Pharmaceuticals PLC Announces Institutional Fundraise
Hemogenyx Pharmaceuticals PLC Announces Annual IND Report with FDA
Hemogenyx Pharmaceuticals PLC Announces Tech Transfer Completion and Clinical Trial Update
Hemogenyx Pharmaceuticals PLC Announces Total Voting Rights
Hemogenyx Pharmaceuticals PLC Announces Exercise of Warrants and Issue of Equity
CORRECTION FROM SOURCE: Hemogenyx Pharmaceuticals PLC Announces Issue of Equity
Hemogenyx Pharmaceuticals PLC Announces Issue of Equity
Hemogenyx Pharmaceuticals PLC Announces Update on Admission of Shares
Hemogenyx Pharmaceuticals PLC - Issue of Equity
Hemogenyx Pharmaceuticals PLC Announces Publication of Prospectus
Hemogenyx shares rise after safety board backs next trial phase for CAR-T therapy
Hemogenyx Pharmaceuticals PLC Announces Clinical Trial Update and Grant of Share Awards
Hemogenyx Pharmaceuticals PLC Announces Clearance to Initiate Pediatric Enrolment
Hemogenyx Pharmaceuticals PLC Announces Half-year Report
Hemogenyx Pharmaceuticals shares rise (again) as it inks agreement to commercialise CAR-T
Hemogenyx Pharmaceuticals PLC Signs Letter of Intent
Hemogenyx rises on progress in CAR-T trial
Hemogenyx Pharmaceuticals PLC Announces Third Patient Safety